In fiscal year 2011, we published a clinical report in collaboration with the primary oncology services regarding the treatment of a cutaneous adverse reaction associated with vandetanib treatment. We continue to evaluate oncology patients at risk for the development of cutaneous toxicities associated with molecularly targeted therapies. These evaluations include baseline evaluations prior to initiation of treatment and follow-up visits to monitor and treat these skin toxicities. We work with oncology colleagues to inform the research community of potentially newly described skin toxicities and methods for management of these adverse effects to optimize continued treatment of oncology patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
O'Sullivan Coyne, Geraldine; Woodring, Therese S; Lee, Chyi-Chia R et al. (2018) Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition of Gamma-Secretase. J Invest Dermatol 138:979-981
Pichard, Dominique C; Cardones, Adela R; Chu, Emily Y et al. (2016) Sorafenib-Induced Eruption Mimicking Erythema Multiforme. JAMA Dermatol 152:227-8
Brooks, Sara; Linehan, W Marston; Srinivasan, Ramaprasad et al. (2011) Successful laser treatment of vandetanib-associated cutaneous pigmentation. Arch Dermatol 147:364-5
Jain, Lokesh; Gardner, Erin R; Figg, William D et al. (2010) Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy 30:52-6
Azad, Nilofer S; Aragon-Ching, Jeanny B; Kong, Heidi H (2009) Clin Cancer Res 15:7749
Azad, Nilofer S; Aragon-Ching, Jeanny B; Dahut, William L et al. (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 15:1411-6
Kong, Heidi H; Turner, Maria L (2009) Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol 61:360-1
Kong, Heidi H; Fine, Howard A; Stern, Jere B et al. (2009) Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol 145:923-5
Lacouture, Mario E; Wu, Shenhong; Robert, Caroline et al. (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001-11
Kong, Heidi H; Sibaud, Vincent; Chanco Turner, Maria L et al. (2008) Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 144:820-2